What is a stock summary page? Click here for an overview.
Business Description
Merus NV
ISIN : NL0011606264
Description
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 54.18 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 12.76 | |||||
| Beneish M-Score | -2.33 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -23.8 | |||||
| 3-Year EBITDA Growth Rate | -22.4 | |||||
| 3-Year EPS without NRI Growth Rate | -19.2 | |||||
| 3-Year FCF Growth Rate | -23.1 | |||||
| 3-Year Book Growth Rate | 9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 66.72 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.4 | |||||
| 9-Day RSI | 50.56 | |||||
| 14-Day RSI | 53.17 | |||||
| 3-1 Month Momentum % | 4.69 | |||||
| 6-1 Month Momentum % | -6.53 | |||||
| 12-1 Month Momentum % | -0.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.54 | |||||
| Quick Ratio | 6.54 | |||||
| Cash Ratio | 6.17 | |||||
| Days Sales Outstanding | 132.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.6 | |||||
| Shareholder Yield % | -13.92 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -752.96 | |||||
| Net Margin % | -595.93 | |||||
| FCF Margin % | -519.37 | |||||
| ROE % | -38.4 | |||||
| ROA % | -31 | |||||
| ROIC % | -174.12 | |||||
| 3-Year ROIIC % | -109.55 | |||||
| ROC (Joel Greenblatt) % | -1231.48 | |||||
| ROCE % | -44.2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 84.54 | |||||
| PB Ratio | 4.99 | |||||
| Price-to-Tangible-Book | 5 | |||||
| EV-to-EBIT | -10.45 | |||||
| EV-to-Forward-EBIT | -7.77 | |||||
| EV-to-EBITDA | -10.54 | |||||
| EV-to-Forward-EBITDA | -7.82 | |||||
| EV-to-Revenue | 78.67 | |||||
| EV-to-Forward-Revenue | 82.87 | |||||
| EV-to-FCF | -15.15 | |||||
| Price-to-GF-Value | 3.15 | |||||
| Price-to-Net-Current-Asset-Value | 7.45 | |||||
| Price-to-Net-Cash | 8.04 | |||||
| Earnings Yield (Greenblatt) % | -9.57 | |||||
| FCF Yield % | -5.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MRUS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Merus NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 36.133 | ||
| EPS (TTM) ($) | -3.27 | ||
| Beta | 0.7 | ||
| 3-Year Sharpe Ratio | 0.5 | ||
| 3-Year Sortino Ratio | 0.89 | ||
| Volatility % | 33.36 | ||
| 14-Day RSI | 53.17 | ||
| 14-Day ATR ($) | 2.144572 | ||
| 20-Day SMA ($) | 46.8775 | ||
| 12-1 Month Momentum % | -0.8 | ||
| 52-Week Range ($) | 37.77 - 61.61 | ||
| Shares Outstanding (Mil) | 69.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Merus NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Merus NV Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Merus NV Frequently Asked Questions
What is Merus NV(MRUS)'s stock price today?
The current price of MRUS is $46.98. The 52 week high of MRUS is $61.61 and 52 week low is $37.77.
When is next earnings date of Merus NV(MRUS)?
The next earnings date of Merus NV(MRUS) is 2025-05-08 Est..
Does Merus NV(MRUS) pay dividends? If so, how much?
Merus NV(MRUS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers